Sacral Nerve Stimulation for Anal Incontinence and Bowel Control

NCT ID: NCT00200005

Last Updated: 2014-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-11-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter European study to evaluate efficacy and safety of sacral nerve stimulation with InterStim Therapy to treat fecal incontinence or constipation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fecal Incontinence and Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

InterStim therapy

Patients being treated with sacral neuromodulation with InterStim therapy.

Group Type EXPERIMENTAL

Type: Implantable neurostimulator; InterStim

Intervention Type DEVICE

Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Type: Implantable neurostimulator; InterStim

Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

InterStim Model 3023 InterStim Model 3058

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fecal incontinence (defined as incontinence to solid or liquid stool \> 1 / week);
* Failed biofeedback or medical therapy;

Groups 1 - 5 patients with:

* Group 1) Circumferentially intact external anal sphincter, no previous surgery;
* Group 2) Circumferentially intact external anal sphincter after surgical repair;
* Group 3) Rectal prolapse repaired with a rectopexy;
* Group 4) Spinal injury including disc prolapse;
* Group 5) Sigmoid or partial rectal resection with colorectal or coloanal anastomosis

Constipation groups:


* Chronic constipation (defined as \</= 2 weekly bowel movements; and/or \>25% of bowel movements required straining; and/or \>25% of bowel movements patient did not feel empty afterwards) with symptoms more than 1 year
* Failed biofeedback or medical therapy;

Groups 6 - 7 patients with:

* Group 6) Idiopathic slow transit constipation as proven on colonic transit studies;
* Group 7) Normal colonic transit studies but chronic constipation due to either pelvic floor dysfunction or disordered defecation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedtronicNeuro

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Klaus Matzel, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Erlangen- Erlangen, Germany

Michael A Kamm, MD

Role: PRINCIPAL_INVESTIGATOR

St. Vincent's Hospital- Melbourne, Australia. Former: St. Mark's Hospital, London, U.K.

Cor Baeten, MD

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Hospital- The Netherlands

John Christiansen, MD

Role: PRINCIPAL_INVESTIGATOR

Herlev Hospital- Copenhagen, Denmark

Anders Mellgren, MD

Role: PRINCIPAL_INVESTIGATOR

Danderyd Hospital- Stockholm, Sweden

Harald Rosen, MD

Role: PRINCIPAL_INVESTIGATOR

Danube Hospital/SMZ-Ost- Vienna, Austria

Albert Navarro, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Mutua de Terrassa- Terrassa, Spain

Robert Madoff, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota- Minneapolis, USA

Carolynne Vaizey, MD

Role: PRINCIPAL_INVESTIGATOR

St. Mark's Hospital- London, UK

Claes Johansson, MD

Role: PRINCIPAL_INVESTIGATOR

Danderyd Hospital- Stockholm, Sweden

Soren Laurberg, MD

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Danube Hospital/SMZ-Ost

Vienna, , Austria

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Herlev Hospital

Copenhagen, , Denmark

Site Status

University Hospital Erlangen

Erlangen, , Germany

Site Status

Maastricht University Hospital

Maastricht, , Netherlands

Site Status

Hospital Mutua de Terrassa

Terrassa, , Spain

Site Status

Danderyd Hospital

Stockholm, , Sweden

Site Status

St. Mark's Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Denmark Germany Netherlands Spain Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet. 1995 Oct 28;346(8983):1124-7. doi: 10.1016/s0140-6736(95)91799-3.

Reference Type BACKGROUND
PMID: 7475602 (View on PubMed)

Matzel KE, Kamm MA, Stosser M, Baeten CG, Christiansen J, Madoff R, Mellgren A, Nicholls RJ, Rius J, Rosen H. Sacral spinal nerve stimulation for faecal incontinence: multicentre study. Lancet. 2004 Apr 17;363(9417):1270-6. doi: 10.1016/S0140-6736(04)15999-0.

Reference Type RESULT
PMID: 15094271 (View on PubMed)

Jarrett ME, Matzel KE, Stosser M, Baeten CG, Kamm MA. Sacral nerve stimulation for fecal incontinence following surgery for rectal prolapse repair: a multicenter study. Dis Colon Rectum. 2005 Jun;48(6):1243-8. doi: 10.1007/s10350-004-0919-y.

Reference Type RESULT
PMID: 15793647 (View on PubMed)

Jarrett ME, Matzel KE, Christiansen J, Baeten CG, Rosen H, Bittorf B, Stosser M, Madoff R, Kamm MA. Sacral nerve stimulation for faecal incontinence in patients with previous partial spinal injury including disc prolapse. Br J Surg. 2005 Jun;92(6):734-9. doi: 10.1002/bjs.4859.

Reference Type RESULT
PMID: 15838899 (View on PubMed)

Jarrett ME, Matzel KE, Stosser M, Christiansen J, Rosen H, Kamm MA. Sacral nerve stimulation for faecal incontinence following a rectosigmoid resection for colorectal cancer. Int J Colorectal Dis. 2005 Sep;20(5):446-51. doi: 10.1007/s00384-004-0729-7. Epub 2005 Apr 21.

Reference Type RESULT
PMID: 15843939 (View on PubMed)

Kamm MA, Dudding TC, Melenhorst J, Jarrett M, Wang Z, Buntzen S, Johansson C, Laurberg S, Rosen H, Vaizey CJ, Matzel K, Baeten C. Sacral nerve stimulation for intractable constipation. Gut. 2010 Mar;59(3):333-40. doi: 10.1136/gut.2009.187989.

Reference Type RESULT
PMID: 20207638 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Mdt-301 (Nov 03, 98),

Identifier Type: -

Identifier Source: secondary_id

Amendment I (Dec 14, 99),

Identifier Type: -

Identifier Source: secondary_id

Amendment II (Jan 31, 02)

Identifier Type: -

Identifier Source: secondary_id

Amendment III (Jul 01, 2009)

Identifier Type: -

Identifier Source: secondary_id

Mdt-301 November 03,1998

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.